Kunwar Shailubhai PhD, MBA, a successful entrepreneur, accomplished scientist and inventor of the widely prescribed drug Trulance, has received the third annual Timothy M. Block, PhD, Biotech Impact Award from the Hepatitis B Foundation, Pennsylvania Biotechnology Center (PABC) and Baruch S. Blumberg Institute.
Dr. Shailubhai received the award at the 25th annual Regional Biotechnology Conference at the PABC Nov. 13, which drew more than 100 professionals in life sciences, finance and related sectors to the Bucks County facility.
Lou Kassa, CEO of the nonprofit PABC and its two sister organizations, said that Dr. Shailubhai, known around the center as Shailu, “hit the trifecta” with the Biotech Impact Award.
“First, Shailu invented a drug that earned FDA approval and now is benefiting patients worldwide,” Kassa said. “He’s also a successful entrepreneur who’s started several biotech companies here at the PABC, two of which are publicly traded. Now he’s been voted by his peers to receive the award named after our founder, Dr. Tim Block. That’s absolutely the trifecta for a PABC member!”
Daiichi Sankyo of Basking Ridge, N.J., was the Presenting Sponsor for this year’s PABC Regional Biotechnology Conference. Proceeds from the event will support research at the Hepatitis B Foundation and Blumberg Institute.
A resident of Line Lexington in Bucks County, Dr. Shailubhai currently is CEO and founder of Nous Biosciences, Inc., an early-stage startup developing drugs in inflammatory diseases and cancer. He has received multiple NIH grants to further develop innovative project concepts.
A professor and senior advisor at the Blumberg Institute for over 25 years, Dr. Shailubhai is on the Drug Inventors Wall of Fame at the PABC. More about Dr. Shailubhai can be found here.
The Pennsylvania Biotechnology Center (PABC): Nearly 100 companies belong to the PABC, which is a nonprofit life sciences incubator and accelerator providing a collaborative ecosystem and state-of-the-art laboratory and office space. There are nearly 70 early-stage biotech companies onsite at the PABC’s two locations. Along with its campus in Doylestown, where a new building with labs and offices opened two years ago, the PABC operates B+labs at Cira Centre in University City, Philadelphia. Launched in 2022, B+labs is a partnership with Brandywine Realty Trust. The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries. PABC companies account for 17% of all National Institutes of Health SBIR grants awarded in Pennsylvania and over the years have created billions of dollars in market value from IPOs, acquisitions and commercial valuations. Visit our website here.
About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is a leading center for translational research in hepatitis B, liver cancer and related diseases. Our scientists primarily focus on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver cancer and therapeutics for the cure of chronic hepatitis B. The Institute’s faculty members have expertise in virology, immunology, cancer biology, chemistry and drug development. Its labs and offices are in the Pennsylvania Biotechnology Center (PABC), which it manages, in Doylestown, Pa. The PABC runs a state-of-the-art incubator in Philadelphia, B+labs at Cira Centre, in partnership with Brandywine Realty Trust. Visit our website and follow us on LinkedIn and X, @BlumbergInstit1.
Kunwar Shailubhai PhD, MBA, a successful entrepreneur, accomplished scientist and inventor of the widely prescribed drug Trulance, has received the third annual Timothy M. Block, PhD, Biotech Impact Award from the Hepatitis B Foundation, Pennsylvania Biotechnology Center (PABC) and Baruch S. Blumberg Institute.
Dr. Shailubhai received the award at the 25th annual Regional Biotechnology Conference at the PABC Nov. 13, which drew more than 100 professionals in life sciences, finance and related sectors to the Bucks County facility.
Lou Kassa, CEO of the nonprofit PABC and its two sister organizations, said that Dr. Shailubhai, known around the center as Shailu, “hit the trifecta” with the Biotech Impact Award.
“First, Shailu invented a drug that earned FDA approval and now is benefiting patients worldwide,” Kassa said. “He’s also a successful entrepreneur who’s started several biotech companies here at the PABC, two of which are publicly traded. Now he’s been voted by his peers to receive the award named after our founder, Dr. Tim Block. That’s absolutely the trifecta for a PABC member!”
Daiichi Sankyo of Basking Ridge, N.J., was the Presenting Sponsor for this year’s PABC Regional Biotechnology Conference. Proceeds from the event will support research at the Hepatitis B Foundation and Blumberg Institute.
A resident of Line Lexington in Bucks County, Dr. Shailubhai currently is CEO and founder of Nous Biosciences, Inc., an early-stage startup developing drugs in inflammatory diseases and cancer. He has received multiple NIH grants to further develop innovative project concepts.
A professor and senior advisor at the Blumberg Institute for over 25 years, Dr. Shailubhai is on the Drug Inventors Wall of Fame at the PABC. More about Dr. Shailubhai can be found here.
The Pennsylvania Biotechnology Center (PABC): Nearly 100 companies belong to the PABC, which is a nonprofit life sciences incubator and accelerator providing a collaborative ecosystem and state-of-the-art laboratory and office space. There are nearly 70 early-stage biotech companies onsite at the PABC’s two locations. Along with its campus in Doylestown, where a new building with labs and offices opened two years ago, the PABC operates B+labs at Cira Centre in University City, Philadelphia. Launched in 2022, B+labs is a partnership with Brandywine Realty Trust. The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries. PABC companies account for 17% of all National Institutes of Health SBIR grants awarded in Pennsylvania and over the years have created billions of dollars in market value from IPOs, acquisitions and commercial valuations. Visit our website here.
About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is a leading center for translational research in hepatitis B, liver cancer and related diseases. Our scientists primarily focus on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver cancer and therapeutics for the cure of chronic hepatitis B. The Institute’s faculty members have expertise in virology, immunology, cancer biology, chemistry and drug development. Its labs and offices are in the Pennsylvania Biotechnology Center (PABC), which it manages, in Doylestown, Pa. The PABC runs a state-of-the-art incubator in Philadelphia, B+labs at Cira Centre, in partnership with Brandywine Realty Trust. Visit our website and follow us on LinkedIn and X, @BlumbergInstit1.